Literature DB >> 34435935

Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine.

Olivia G Cohen1, Ashley K Clark1, Heather Milbar1, Mordechai Tarlow2.   

Abstract

Pityriasis rosea (PR) is an acute papulosquamous cutaneous disorder that classically presents with a herald patch rapidly followed by a widespread rash along skin cleavage lines. Although the exact pathogenesis of PR is unknown, current evidence suggests that an inflammatory reaction due to a viral trigger may lead to the cutaneous manifestations. COVID-19 has been reported as one such viral trigger for PR. Previously, PR has been reported in temporal association with various viral inoculations. This article presents a case of PR in a 66-year-old black male 1 week after administration of the Pfizer-BioNTech COVID-19 vaccine.

Entities:  

Keywords:  COVID-19; Vaccination; pityriasis rosea

Mesh:

Substances:

Year:  2021        PMID: 34435935      PMCID: PMC8828149          DOI: 10.1080/21645515.2021.1963173

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  8 in total

1.  Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6.

Authors:  Takahiro Watanabe; Tatsuyoshi Kawamura; Sharon E Jacob; Elisabeth A Aquilino; Jan M Orenstein; Jodi B Black; Andrew Blauvelt
Journal:  J Invest Dermatol       Date:  2002-10       Impact factor: 8.551

2.  Uncommon presentation of pityriasis rosea after yellow fever inoculation.

Authors:  Piotr Brzezinski; Anca Chiriac
Journal:  JAMA Dermatol       Date:  2014-09       Impact factor: 10.282

3.  Pityriasis rosea following influenza (H1N1) vaccination.

Authors:  Jeng-Feng Chen; Chien-Ping Chiang; Yu-Fei Chen; Wei-Ming Wang
Journal:  J Chin Med Assoc       Date:  2011-05-12       Impact factor: 2.743

Review 4.  Pityriasis Rosea: A Comprehensive Classification.

Authors:  Francesco Drago; Giulia Ciccarese; Alfredo Rebora; Francesco Broccolo; Aurora Parodi
Journal:  Dermatology       Date:  2016-04-21       Impact factor: 5.366

5.  An atypical case of pityriasis rosea gigantea after influenza vaccination.

Authors:  Dimitrios Papakostas; Panagiotis G Stavropoulos; Dafni Papafragkaki; Ekaterini Grigoraki; Georgia Avgerinou; Christina Antoniou
Journal:  Case Rep Dermatol       Date:  2014-04-18

6.  Recurrent pityriasis rosea: A case report.

Authors:  Ang Li; Ping Li; Yanqiong Li; Wenfei Li
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

7.  Pityriasis rosea following human papillomavirus vaccination.

Authors:  Francesco Drago; Giulia Ciccarese; Alfredo Rebora; Aurora Parodi
Journal:  Braz J Infect Dis       Date:  2014-12-17       Impact factor: 3.257

8.  Pityriasis rosea and COVID-19.

Authors:  Stefano Veraldi; Cristina B Spigariolo
Journal:  J Med Virol       Date:  2020-12-01       Impact factor: 20.693

  8 in total
  2 in total

Review 1.  SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.

Authors:  Gianluca Avallone; Pietro Quaglino; Francesco Cavallo; Gabriele Roccuzzo; Simone Ribero; Iris Zalaudek; Claudio Conforti
Journal:  Int J Dermatol       Date:  2022-02-09       Impact factor: 3.204

Review 2.  Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review.

Authors:  George Kroumpouzos; Maria Eleni Paroikaki; Sara Yumeen; Shashank Bhargava; Eleftherios Mylonakis
Journal:  Microorganisms       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.